{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:29Z","timestamp":1792834709536,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Photodiagnosis and Photodynamic Therapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pdpdt.2026.105687","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:15Z","timestamp":1792022415000},"page":"105687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Epivascular glia and macular pigment changes after faricimab or aflibercept during the loading phase in diabetic macular edema: a prospective non-randomized pilot study"],"prefix":"10.1016","volume":"62","author":[{"given":"Gilda","family":"Cennamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Caporale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Tramontano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Costagliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pdpdt.2026.105687_bib0001","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.ophtha.2018.04.007","article-title":"Guidelines on diabetic retinopathy","volume":"125","author":"Wong","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pdpdt.2026.105687_bib0002","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pdpdt.2026.105687_bib0003","first-page":"557","article-title":"Diabetic retinopathy: seeing beyond glucose- induced microvascular disease","volume":"8","author":"Antonetti","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0004","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.3390\/ijms23158513","article-title":"New insights into treating early and advanced stage diabetic retinopathy","volume":"23","author":"Simo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2023.103688","article-title":"Evaluation of changes in epivascular glia before and after intravitreal dexamethasone implant: an OCT pilot study","volume":"43","author":"Cennamo","year":"2023","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0006","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.preteyeres.2006.05.003","article-title":"Muller cells in the healthy and diseased retina","volume":"25","author":"Bringmann","year":"2006","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0007","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2021.03.014","article-title":"Identification and characterization of epivascular glia using en face optical coherence tomography","volume":"229","author":"Grondin","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0008","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.pdpdt.2026.105687_bib0009","first-page":"193","article-title":"Faricimab for retinal vascular diseases: bispecific inhibition of Ang-2\/VEGF-A","volume":"30","author":"Nicolo","year":"2021","journal-title":"Expert Opin. Investig. Drug."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0010","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pdpdt.2026.105687_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1192464","article-title":"Angiopoietin-2 inhibition reduces vascular permeability and neuroinflammation in retinal ischemia-reperfusion injury","volume":"17","author":"Canonica","year":"2023","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0012","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1097\/IAE.0000000000004572","article-title":"Impact of faricimab versus aflibercept on epiretinal membrane formation over 2 years in patients with diabetic macular edema in the phase 3 YOSEMITE and RHINE trials","volume":"45","author":"Jaffe","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.pdpdt.2026.105687_bib0013","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1167\/tvst.13.12.32","article-title":"Phase 1b dose escalation study of sozinibercept inhibition of vascular endothelial growth factors C and D with aflibercept for diabetic macular edema","volume":"13","author":"Boyer","year":"2024","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0014","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/bjophthalmol-2020-318690","article-title":"Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study","volume":"106","author":"Liu","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0002-9440(10)63952-1","article-title":"Leukocyte-mediated endothelial cell injury and death in the diabetic retina","volume":"158","author":"Joussen","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.pdpdt.2026.105687_bib0016","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"}],"container-title":["Photodiagnosis and Photodynamic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100026003534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100026003534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:57:21Z","timestamp":1792832241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1572100026003534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":16,"alternative-id":["S1572100026003534"],"URL":"https:\/\/doi.org\/10.1016\/j.pdpdt.2026.105687","relation":{},"ISSN":["1572-1000"],"issn-type":[{"value":"1572-1000","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epivascular glia and macular pigment changes after faricimab or aflibercept during the loading phase in diabetic macular edema: a prospective non-randomized pilot study","name":"articletitle","label":"Article Title"},{"value":"Photodiagnosis and Photodynamic Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pdpdt.2026.105687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105687"}}